Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Back

Showing results (71-80 of 147) with videos related to

Pageof 15
Sort By:
The Journal of Antimicrobial Chemotherapy|September 21, 2006
Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patientsJennifer Ford, Marta Boffito, Desmond Maitland, et al.
The Journal of Antimicrobial Chemotherapy|February 22, 2005
Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice dailyMarta Boffito, Desmond Maitland, Laura Dickinson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 18, 2015
Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: an observational studyAdeniyi Olagunju, Oluseye Bolaji, Alieu Amara, et al.
Antiviral Therapy|January 24, 2012
Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjectsAkil Jackson, Graeme Moyle, Laura Dickinson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 22, 2009
Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteersMarta Boffito, Akil Jackson, Mohammed Lamorde, et al.
Antimicrobial Agents and Chemotherapy|June 25, 2004
Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patientsJennifer Ford, Marta Boffito, Adrian Wildfire, et al.
Antiviral Research|July 31, 2012
Anti-retroviral drugs do not facilitate hepatitis C virus (HCV) infection in vitroLisa Sandmann, Matthew Wilson, David Back, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 16, 2004
Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patientsMarta Boffito, Laura Dickinson, Andrew Hill, et al.
HIV Clinical Trials|March 18, 2015
The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of ageJaime H Vera, Akil Jackson, Laura Dickinson, et al.
The Journal of Infectious Diseases|November 14, 2015
Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA)Kerri J Penrose, Urvi M Parikh, Kristen A Hamanishi, et al.
Pageof 15

Showing results (71-80 of 147) with videos related to

Sort By:
Pageof 15
The Journal of Antimicrobial Chemotherapy|September 21, 2006
Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patientsJennifer Ford, Marta Boffito, Desmond Maitland, et al.
The Journal of Antimicrobial Chemotherapy|February 22, 2005
Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice dailyMarta Boffito, Desmond Maitland, Laura Dickinson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 18, 2015
Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: an observational studyAdeniyi Olagunju, Oluseye Bolaji, Alieu Amara, et al.
Antiviral Therapy|January 24, 2012
Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjectsAkil Jackson, Graeme Moyle, Laura Dickinson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 22, 2009
Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteersMarta Boffito, Akil Jackson, Mohammed Lamorde, et al.
Antimicrobial Agents and Chemotherapy|June 25, 2004
Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patientsJennifer Ford, Marta Boffito, Adrian Wildfire, et al.
Antiviral Research|July 31, 2012
Anti-retroviral drugs do not facilitate hepatitis C virus (HCV) infection in vitroLisa Sandmann, Matthew Wilson, David Back, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 16, 2004
Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patientsMarta Boffito, Laura Dickinson, Andrew Hill, et al.
HIV Clinical Trials|March 18, 2015
The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of ageJaime H Vera, Akil Jackson, Laura Dickinson, et al.
The Journal of Infectious Diseases|November 14, 2015
Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA)Kerri J Penrose, Urvi M Parikh, Kristen A Hamanishi, et al.
Pageof 15